Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.

Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, Brooks KA, Cohen S, Tenenholz B, Desai D, Zandvakili I, Royer R, Li S, Narod SA.

BMC Cancer. 2009 Mar 19;9:86. doi: 10.1186/1471-2407-9-86.

2.

The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications.

Honrado E, Benítez J, Palacios J.

Mod Pathol. 2005 Oct;18(10):1305-20. Review.

3.

BRCA1/2 mutations and triple negative breast cancers.

Peshkin BN, Alabek ML, Isaacs C.

Breast Dis. 2010;32(1-2):25-33. doi: 10.3233/BD-2010-0306. Review.

4.

The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer.

Newman LA, Reis-Filho JS, Morrow M, Carey LA, King TA.

Ann Surg Oncol. 2015 Mar;22(3):874-82. doi: 10.1245/s10434-014-4279-0. Epub 2014 Dec 20. Review.

PMID:
25527230
5.

Familial non-BRCA1/BRCA2-associated breast cancer.

Eccles DM, Pichert G.

Lancet Oncol. 2005 Sep;6(9):705-11. Review.

PMID:
16129371
6.

Genetic susceptibility to triple-negative breast cancer.

Stevens KN, Vachon CM, Couch FJ.

Cancer Res. 2013 Apr 1;73(7):2025-30. doi: 10.1158/0008-5472.CAN-12-1699. Epub 2013 Mar 27. Review.

7.

Triple-negative breast cancer: therapeutic options.

Cleator S, Heller W, Coombes RC.

Lancet Oncol. 2007 Mar;8(3):235-44. Review.

PMID:
17329194
8.

[Case of encapsulated solid papillary carcinoma with triple-negative and basal-like phenotype occurred in pregnant woman with review of the literature].

Popovska S, Damianova P, Tomov S, Dineva T, Ivanov I.

Akush Ginekol (Sofiia). 2015;54(2):50-6. Review. Bulgarian.

PMID:
25909142
9.

BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer.

Diaz-Cruz ES, Cabrera MC, Nakles R, Rutstein BH, Furth PA.

Breast Dis. 2010;32(1-2):85-97. doi: 10.3233/BD-2010-0308. Review.

10.

Treatment options for patients with triple-negative breast cancer.

Santana-Davila R, Perez EA.

J Hematol Oncol. 2010 Oct 27;3:42. doi: 10.1186/1756-8722-3-42. Review.

11.

[Predictive markers in breast cancer treatment--focusing on a recent topic "basal-like breast cancer"].

Koike A, Ohta T.

Nihon Rinsho. 2007 Jun 28;65 Suppl 6:285-90. Review. Japanese. No abstract available.

PMID:
17682168
12.

Germline Mutations in Triple-Negative Breast Cancer.

Hahnen E, Hauke J, Engel C, Neidhardt G, Rhiem K, Schmutzler RK.

Breast Care (Basel). 2017 Mar;12(1):15-19. doi: 10.1159/000455999. Epub 2017 Feb 24. Review.

PMID:
28611536
13.

The future of breast cancer systemic therapy: the next 10 years.

Telli ML, Sledge GW.

J Mol Med (Berl). 2015 Feb;93(2):119-25. doi: 10.1007/s00109-014-1238-y. Epub 2015 Jan 9. Review.

PMID:
25566982
14.

Genetics of triple-negative breast cancer: Implications for patient care.

Afghahi A, Telli ML, Kurian AW.

Curr Probl Cancer. 2016 Mar - Aug;40(2-4):130-140. doi: 10.1016/j.currproblcancer.2016.09.007. Epub 2016 Sep 23. Review.

PMID:
28340968
15.

Hormone responsive breast cancer and BRCA1 mutation: mechanism, regulation and iron-mediated effects.

Zghair AN, Sharma R, Sharma AK.

Curr Pharm Biotechnol. 2014;15(12):1113-24. Review.

PMID:
25429655
16.

Breast Cancer in Pakistan a Critical Appraisal of the Situation Regarding Female Health and Where the Nation Stands?

Basra MA, Saher M, Athar MM, Raza MH.

Asian Pac J Cancer Prev. 2016;17(7):3035-41. Review.

17.

[Triple Negative Breast Cancer].

Navrátil J, Fabian P, Palácová M, Petráková K, Vyzula R, Svoboda M.

Klin Onkol. 2015;28(6):405-15. Review. Czech.

PMID:
26673990
18.

Molecular structure of BRCA1-estrogen receptor alpha-estrogen complex: relevance to breast cancer?

Wiwanitkit V.

Asian Pac J Cancer Prev. 2005 Oct-Dec;6(4):561-2. Review.

19.

Breast cancer in young women.

Narod SA.

Nat Rev Clin Oncol. 2012 Jun 26;9(8):460-70. doi: 10.1038/nrclinonc.2012.102. Review.

PMID:
22733233
20.

Advances in breast cancer: pathways to personalized medicine.

Olopade OI, Grushko TA, Nanda R, Huo D.

Clin Cancer Res. 2008 Dec 15;14(24):7988-99. doi: 10.1158/1078-0432.CCR-08-1211. Review.

Supplemental Content

Support Center